RecruitingPhase 1Phase 2NCT06717815

Phase IIa Study for IPG11406 in Patients With Lupus Nephritis

A Multi-center, Multi-dose Phase Ib/IIa Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy, Pharmacokinetics, and Impact on Biomarkers of IPG11406 in Patients With Lupus Nephritis

Sponsor

Nanjing Immunophage Biotech Co., Ltd

Enrollment

36 participants

Start Date

Feb 25, 2025

Study Type

INTERVENTIONAL

Conditions

Lupus Nephritis

Summary

A multi-center, multi-dose phase Ib/IIa clinical study evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics, and impact on biomarkers of IPG11406 in patients with Lupus Nephritis

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called IPG11406 for people with lupus nephritis. The study is currently recruiting participants at 17 locations. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIPG11406

Investigational Medical Products: IPG11406 Activity: An antagonist of the GPR183 Dosage form: Tablet Strength: 10 mg and 40 mg Storage：15 \~ 25 °C in a tightly sealed container, protect from light Administration: In each cohort, IPG11406 tablets are orally administered twice a Day with an interval of 12±1 hours. Tablets should not be chewed or crushed.

Locations(17)

The First Affiliated Hospital Of Anhui Medical University

Hefei, Anhui, China

Fujian Medical University Union Hospital

Fuzhou, Fujian, China

Fujian Provincial Hospital

Fuzhou, Fujian, China

Sun Yai-sen Memorial Hospital, Sun Yai-sen University

Guangzhou, Guandong, China

Hebei Petro China Central Hospital

Langfang, Hebei, China

Xinxiang Central Hospital

Xinxiang, Henan, China

Renmin Hospital of Wuhan University

Wuhan, Hubei, China

Wuhan Hospital of Traditional Chinese and Western Medicine

Wuhan, Hubei, China

Xiangya Hospital of Central South University

Changsha, Hunan, China

Nanjing DrumTower Hospital of Nanjing University Medical School

Nanjing, Jiangsu, China

Nantong First People's Hospital

Nantong, Jiangsu, China

The Affiliated Hospital of Xuzhou Medical University

Xuzhou, Jiangsu, China

The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China

Shandong Provincial Hospital

Jinan, Shandong, China

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, China

West China Hospital, Sichuan University

Chengdu, Sichuan, China

Jinhua Municipal Centeral Hospital Medical Group

Jinhua, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06717815

Related Trials

PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

NCT0761121415 locations

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

NCT0692554214 locations

US Zamto-cel Autoimmune Diseases

NCT067088451 location

A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

NCT0655726519 locations

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

NCT06581198101 locations